Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Regeneron Pharmaceuticals, Inc. descubre, inventa, desarrolla, fabrica y comercializa medicamentos para tratar diversas enfermedades en todo el mundo. La empresa desarrolla productos candidatos para tratar enfermedades oculares, alérgicas e inflamatorias, cardiovasculares, metabólicas, neurológicas, infecciosas y raras; y cáncer, condiciones hematológicas.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $15.5B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $7.9B | $6.7B | $5.9B | $4.9B | $4.1B | $2.8B | $2.1B | $1.4B | $446M | $459M | $379M | $238M | $125M | $63M |
| Beneficio bruto | $13.2B | $12.2B | $12.2B | $12.2B | $10.5B | $13.3B | $7.1B | $7.1B | $6.3B | $5.5B | $4.6B | $3.7B | $2.6B | $1.9B | $1.3B | $442M | $457M | $363M | $238M | $125M | $41M |
| % de margen bruto | 84.9% | 85.4% | 86.1% | 93.3% | 86.0% | 83.0% | 84.0% | 90.0% | 93.5% | 93.2% | 93.8% | 90.4% | 92.7% | 92.6% | 93.9% | 99.1% | 99.5% | 95.8% | 99.6% | 100.0% | 64.2% |
| Ingresos operativos (EBIT) | $4.0B | $3.6B | $4.0B | $4.0B | $5.4B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $838M | $760M | $458M | ($205M) | ($97M) | ($74M) | ($90M) | ($114M) | ($107M) |
| % de margen operativo | 25.6% | 24.9% | 28.1% | 30.9% | 44.2% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | 36.1% | 33.2% | -46.0% | -21.2% | -19.5% | -37.7% | -91.5% | -169.1% |
| Ingresos netos | $4.3B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M | $636M | $348M | $424M | $750M | ($222M) | ($104M) | ($68M) | ($83M) | ($106M) | ($102M) |
| % de margen neto | 27.9% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | 20.2% | 54.4% | -49.7% | -22.8% | -17.9% | -34.7% | -84.5% | -161.3% |
| EBITDA | $5.8B | $5.8B | $5.3B | $4.0B | $5.3B | $9.7B | $4.1B | $2.4B | $2.7B | $2.2B | $1.4B | $1.3B | $891M | $801M | $495M | ($174M) | ($78M) | ($55M) | ($79M) | ($82M) | ($77M) |
| Beneficio por acción (EPS) | $40.37 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $3.07 | $3.81 | $6.50 | $-2.45 | $-1.26 | $-0.85 | $-1.05 | $-1.59 | $-1.77 |
| Acciones en circulación (M) | 107M | 109M | 115M | 114M | 114M | 112M | 115M | 115M | 115M | 116M | 116M | 115M | 113M | 111M | 115M | 91M | 83M | 80M | 79M | 66M | 58M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de REGN. /companies/us/REGN
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms